Vor Biopharma (VOR) Operating Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Expenses data on file, last reported at $35.2 million in Q1 2026.

• Quarterly Operating Expenses rose 5.61% year-over-year to $35.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.5 million (up 205.78% YoY) and the FY2025 annual result came in at $371.6 million, up 206.67% from the prior year.
• Operating Expenses eased to $35.2 million in Q1 2026 per VOR's latest filing, from $36.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $274.3 million in Q2 2025 and bottomed at $21.8 million in Q2 2022.
• The 5-year median for Operating Expenses is $30.4 million (2023), against an average of $44.0 million.
• The widest annual swing landed in 2024, when Operating Expenses declined 19.26%; it then surged 844.67% in 2025.
• Tracing VOR's Operating Expenses over 5 years: stood at $24.7 million in 2022, then gained by 13.75% to $28.1 million in 2023, then rose by 11.33% to $31.3 million in 2024, then rose by 14.85% to $36.0 million in 2025, then declined by 2.22% to $35.2 million in 2026.
• Per Business Quant, the three latest VOR Operating Expenses figures stand at $35.2 million (Q1 2026), $36.0 million (Q4 2025), and $28.1 million (Q3 2025).

Peer Comparison